Skye Bioscience (SKYE) Appoints Paul Grayson as Chairman
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- Wall St falls as Trump's Iran remarks weigh on markets
- Oil jumps around 5% to two-week high after Trump warns of more attacks on Iran
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board
October 29, 2024 7:00 AM EDTSAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (Skye), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced the Board has appointed independent director Paul Grayson as Skyes new Chairman of the Board, effective October 25, 2024. Mr. Grayson currently serves as a member of Skyes Audit, Compensation and Nominating and Corporate Governance Committees. Punit Dhillon, Skyes Chief Executive Officer, will continue to serve as a member of the Board.
Punit Dhillon, Skyes Chief Executive Officer and former Chairman of the... More
